Headlines about Check-Cap (NASDAQ:CHEK) have been trending positive on Wednesday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Check-Cap earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 46.0406800769513 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of analysts recently issued reports on the company. Zacks Investment Research cut Check-Cap from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. ValuEngine raised Check-Cap from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 17th. Maxim Group reissued a “buy” rating and set a $5.00 target price on shares of Check-Cap in a research note on Wednesday, September 27th. Finally, HC Wainwright set a $6.00 target price on Check-Cap and gave the stock a “buy” rating in a research note on Friday, August 11th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Check-Cap currently has a consensus rating of “Buy” and an average price target of $5.00.
Check-Cap (NASDAQ CHEK) traded down 2.8139% during mid-day trading on Wednesday, reaching $1.2537. The company had a trading volume of 78,226 shares. Check-Cap has a one year low of $1.17 and a one year high of $2.91. The firm’s market capitalization is $21.29 million. The firm’s 50-day moving average is $1.75 and its 200-day moving average is $1.75.
Check-Cap (NASDAQ:CHEK) last issued its quarterly earnings results on Thursday, August 10th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01). On average, equities research analysts anticipate that Check-Cap will post ($0.63) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Check-Cap (CHEK) Earns News Sentiment Score of 0.26” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/11/01/check-cap-chek-earns-news-sentiment-score-of-0-26.html.
Check-Cap Company Profile
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.
What are top analysts saying about Check-Cap Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Check-Cap Ltd. and related companies.